All In Biotech

Drug Trial Radar · NCT06555549

Efficacy and Safety of DEH113 in the Treatment of Menstrual Cramp Pain in Primary Dysmenorrhea: a Pilot Study

A National, Multicenter, Randomized, Double-blind, Single-dose, Crossover Clinical Trial to Preliminary Evaluate the Efficacy and Safety of DEH113 in the Treatment of Menstrual Cramps Pain Associated With Primary Dysmenorrhea

Last checked: Nov 19, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 2024

Primary completion

Sep 2025

Study completion Feb 2026

Sponsor

Lead sponsor
EMSIndustry
Sponsor type
Industry
First posted
Aug 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 16 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the preliminary efficacy and safety of DEH113 in the Treatment of Menstrual Cramps Pain Associated with Primary Dysmenorrhea.

Conditions

  • Primary Dysmenorrhea

Interventions

  • DEH113Drug

    tablets

  • PlaceboDrug

    tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sum of Total Pain Relief (TOTPAR) over 0-4, 0-6 and 0-8 hours post-doseTime frame: 4, 6 and 8 hours post-dose
  2. Sum of Pain Intensity Difference (SPID) over 4, 6 and 8 hours post-doseTime frame: 4, 6 and 8 hours post-dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.